This study is designed to determine whether the addition of cetuximab to standard chemotherapy and radiation reduces the failure rate of this therapy. All participants will be given combined modality therapy (chemotherapy and radiation) plus cetuximab. Participants will be followed for up to 5 years.

Inclusion Criteria:

• Men and women 18 years or older
• Documented HIV infection
• Biopsy proven stage I to IIIB invasive anal canal or perianal squamous cell cancer.

Exclusion criteria:

• Current active serious opportunistic infection
• A CD4 cell count below 50 mL if in conjunction with an opportunistic infection within the past 6 months
• Prior invasive cancer within the last two years
• Grade 2, 3 or 4 neuropathy
• Severe or poorly controlled diarrhea
• Pregnancy or breast feeding

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #06-05-094-01

If you think you might be interested in participating in this study, please contact Deon Claiborne at 310-557-9062 or email at dclaiborne@mednet.ucla.edu

Return to Clinical Trials main page